MoonLake Immunotherapeutics (MLTX) to Release Quarterly Earnings on Thursday

MoonLake Immunotherapeutics (NASDAQ:MLTX) is expected to be posting its quarterly earnings results before the market opens on Thursday, March 6th. Analysts expect MoonLake Immunotherapeutics to post earnings of ($0.53) per share for the quarter.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.09). On average, analysts expect MoonLake Immunotherapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

MoonLake Immunotherapeutics Stock Up 4.0 %

NASDAQ MLTX opened at $42.37 on Thursday. The company has a market capitalization of $2.71 billion, a price-to-earnings ratio of -32.84 and a beta of 1.28. MoonLake Immunotherapeutics has a twelve month low of $37.55 and a twelve month high of $58.26. The stock has a fifty day simple moving average of $46.90 and a 200 day simple moving average of $48.99.

Analyst Ratings Changes

A number of brokerages have commented on MLTX. Wedbush reaffirmed an “outperform” rating and set a $73.00 price target (down previously from $92.00) on shares of MoonLake Immunotherapeutics in a research report on Tuesday, November 5th. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price target on shares of MoonLake Immunotherapeutics in a research report on Friday, January 10th. Finally, The Goldman Sachs Group raised shares of MoonLake Immunotherapeutics from a “neutral” rating to a “buy” rating and upped their price target for the company from $62.00 to $82.00 in a research report on Friday, January 17th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, MoonLake Immunotherapeutics presently has an average rating of “Buy” and a consensus target price of $84.20.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.